6.2.4.5	  Guidelines for radical- and palliative treatment of locally-advanced disease*,
Recommendations   Strength rating,
Radical prostatectomy (RP),
Offer RP to patients with cN0 disease as part of multi-modal therapy.   Weak,
Extended pelvic lymph node dissection (ePLND),
Perform an ePLND.   Strong,
Radiotherapeutic treatments,
Offer patients with cN0 disease intensity-modulated radiation therapy (IMRT)/volumetric   modulated arc therapy (VMAT) plus image-guide radiation therapy in combination with    long-term androgen deprivation therapy (ADT).,Strong
"Offer patients with cN0 disease and good urinary function, IMRT/VMAT plus IGRT with   brachytherapy boost (either high-dose rate or low-dose rate), in combination with long-term   ADT.",Weak
Offer long-term ADT for at least 2 years.,Strong
"Offer IMRT/VMAT plus IGRT to the prostate in combination with long-term ADT and 2 years   of abiraterone to cN0M0 patients with > 2 high-risk factors (cT3-4, Gleason > 8 or PSA > 40   ng/mL).",Strong
Offer IMRT/VMAT plus IGRT to the prostate plus pelvis in combination with long-term ADT   and 2 years of abiraterone to cN1M0 patients.,Strong
Offer patients with cN1 disease a local treatment (either RP or IMRT/VMAT plus IGRT) plus   long-term ADT.,Strong
Therapeutic options outside surgery or radiotherapy,
Do not offer whole gland treatment or focal treatment.  Strong,
